UBS lowered the firm’s price target on Zoetis (ZTS) to $158 from $165 and keeps a Neutral rating on the shares. The firm is incrementally cautious on Zoetis into the print.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZTS:
- Zoetis announces Health Canada approval for Lenivia
- Buy Rating on Zoetis: Strategic Initiatives and Long-term Growth Potential Amid Short-term Challenges
- Zoetis’s Strategic Launch of Innovative Monoclonal Antibodies for Osteoarthritic Pain Management
- Zoetis receives positive opinion from CVMP for Lenivia
- Zoetis Declares Q4 2025 Dividend of $0.50